LABAs, tiotropium perform similarly in black patients with asthma

This article originally appeared here.
When added to ICS, tiotropium and LABAs perform similarly for asthma patients.
When added to ICS, tiotropium and LABAs perform similarly for asthma patients.

HealthDay News — For black patients with asthma treated with inhaled corticosteroids (ICS), outcomes are similar with addition of tiotropium and long-acting β-agonists (LABAs), according to a study published in the Journal of the American Medical Association.

Michael E. Wechsler, MD, from Brigham and Women's Hospital in Boston, and colleagues conducted a multisite study to compare the effectiveness and safety of tiotropium versus LABAs when used with ICS in black adults with asthma. Patients received ICS plus once-daily tiotropium (532 patients) or twice-daily LABAs (538 patients).

The researchers found that the time to first exacerbation did not differ for LABA + ICS versus tiotropium + ICS (rate ratio, 0.90; 95% confidence interval, 0.73 to 1.11; P = 0.31). No difference was seen in the change in forced expiratory volume in one second between the groups at 12 months (between-group difference, 0.020; P = 0.33) or 18 months (between-group difference, 0.025; P = 0.49). No between-group differences were seen in the Asthma Control Questionnaire score at 18 months (between-group difference, 0.04; P = 0.70). Other patient-reported outcomes also did not differ between the groups. Arg16Gly ADRB2 alleles were not associated with the effects of tiotropium + ICS versus LABA + ICS (P = 0.97).

"These findings do not support the superiority of LABA + ICS compared with tiotropium + ICS for black patients with asthma," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


  1. Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. JAMA. 2015;314(16):1720-1730.
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters